SK14982000A3 - Spôsob inhibície mrp1 - Google Patents

Spôsob inhibície mrp1 Download PDF

Info

Publication number
SK14982000A3
SK14982000A3 SK1498-2000A SK14982000A SK14982000A3 SK 14982000 A3 SK14982000 A3 SK 14982000A3 SK 14982000 A SK14982000 A SK 14982000A SK 14982000 A3 SK14982000 A3 SK 14982000A3
Authority
SK
Slovakia
Prior art keywords
methyl
compound
dihydro
isoxazolo
substituted
Prior art date
Application number
SK1498-2000A
Other languages
English (en)
Slovak (sk)
Inventor
Joseph Michael Gruber
Bryan Hurst Norman
Julian Stanley Kroin
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of SK14982000A3 publication Critical patent/SK14982000A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Control Of The Air-Fuel Ratio Of Carburetors (AREA)
  • Magnetically Actuated Valves (AREA)
SK1498-2000A 1998-04-08 1999-04-07 Spôsob inhibície mrp1 SK14982000A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8108098P 1998-04-08 1998-04-08
PCT/US1999/007613 WO1999051228A1 (en) 1998-04-08 1999-04-07 Methods for inhibiting mrp1

Publications (1)

Publication Number Publication Date
SK14982000A3 true SK14982000A3 (sk) 2001-05-10

Family

ID=22161981

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1498-2000A SK14982000A3 (sk) 1998-04-08 1999-04-07 Spôsob inhibície mrp1

Country Status (18)

Country Link
US (1) US6369070B1 (hr)
EP (1) EP1067928A4 (hr)
JP (1) JP2002510625A (hr)
KR (1) KR20010042471A (hr)
CN (1) CN1304306A (hr)
AU (1) AU3476999A (hr)
BR (1) BR9910112A (hr)
CA (1) CA2327617A1 (hr)
EA (1) EA200001034A1 (hr)
HR (1) HRP20000646A2 (hr)
HU (1) HUP0101508A3 (hr)
ID (1) ID27364A (hr)
IL (1) IL138389A0 (hr)
NO (1) NO20005023L (hr)
PL (1) PL343313A1 (hr)
SK (1) SK14982000A3 (hr)
TR (1) TR200002851T2 (hr)
WO (1) WO1999051228A1 (hr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027116A2 (en) * 1999-10-07 2001-04-19 Eli Lilly And Company Condensed dihydroquinolinone derivatives for inhibiting mrp1
US6743794B2 (en) 1999-12-22 2004-06-01 Eli Lilly And Company Methods and compounds for inhibiting MRP1
AU2251901A (en) * 1999-12-22 2001-07-03 Eli Lilly And Company Methods and compounds for inhibiting MRP1
AU7489101A (en) 2000-06-14 2001-12-24 Lilly Co Eli Tricyclic compounds as mrp1-inhibitors
AU2001294518A1 (en) * 2000-09-22 2002-04-02 Eli Lilly And Company Stereoselective process for preparing cyclohexyl amine derivatives
WO2002081481A1 (en) * 2001-04-09 2002-10-17 Eli Lilly And Company Compounds and methods for inhibiting mrp1
US7101891B2 (en) 2001-04-09 2006-09-05 Eli Lilly And Company Compounds and pharmaceutical compositions for inhibiting MRP1
ATE311392T1 (de) * 2001-04-09 2005-12-15 Lilly Co Eli Verbindungen und methoden zur inhibierung von mrp1
WO2005048948A2 (en) * 2003-11-13 2005-06-02 Ambit Biosciences Corporation Urea derivatives as kinase modulators
KR20070034993A (ko) * 2004-05-14 2007-03-29 아이알엠 엘엘씨 Ｐｐａｒ 조절제로서의 화합물 및 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588731A (en) * 1985-06-21 1986-05-13 Roussel Uclaf Derivatives of isoxazolo[4,5-c]quinoline(2H)-3-one and method of preparation and use as anxiolytic agents
US5744485A (en) * 1994-03-25 1998-04-28 Vertex Pharmaceuticals Incorporated Carbamates and ureas as modifiers of multi-drug resistance
US5717092A (en) 1996-03-29 1998-02-10 Vertex Pharmaceuticals Inc. Compounds with improved multi-drug resistance activity

Also Published As

Publication number Publication date
IL138389A0 (en) 2001-10-31
US6369070B1 (en) 2002-04-09
JP2002510625A (ja) 2002-04-09
AU3476999A (en) 1999-10-25
EA200001034A1 (ru) 2001-04-23
CN1304306A (zh) 2001-07-18
EP1067928A1 (en) 2001-01-17
KR20010042471A (ko) 2001-05-25
HUP0101508A3 (en) 2002-04-29
HUP0101508A2 (hu) 2001-10-28
NO20005023D0 (no) 2000-10-05
EP1067928A4 (en) 2001-11-14
CA2327617A1 (en) 1999-10-14
HRP20000646A2 (en) 2001-06-30
TR200002851T2 (tr) 2000-12-21
BR9910112A (pt) 2000-12-26
PL343313A1 (en) 2001-08-13
WO1999051228A1 (en) 1999-10-14
ID27364A (id) 2001-04-05
NO20005023L (no) 2000-12-05

Similar Documents

Publication Publication Date Title
TW200307539A (en) Cycloalkyl inhibitors of potassium channel function
US6670373B1 (en) Compounds and method for inhibiting MRP1
SK171197A3 (en) 4-phenylaminothiazole derivatives, method for preparing same, and pharmaceutical compositions containing said derivatives
SK14982000A3 (sk) Spôsob inhibície mrp1
US20090149488A1 (en) Tetrahydroprotoberberine Compounds, the Synthetic Method and the Use Thereof
BRPI0620090A2 (pt) diazepinonas
AU715493B2 (en) Selective beta 3 adrenergic agonists
WO2007080109A1 (en) Substituded benzyloxy-phenylmethylurea derivatives
WO2015113521A1 (zh) 氘代喹唑啉酮化合物以及包含该化合物的药物组合物
US6673809B2 (en) Tricyclic compounds as MRP1-inhibitors
WO2022022388A1 (zh) 一种地佐辛衍生物晶型a及其制备方法和应用
SK15002000A3 (sk) Oxazolchinolónové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie na inhibíciu mrp1 u cicavcov
US6221876B1 (en) Methods for inhibiting MRP1
US6686376B2 (en) Methods and compounds for inhibiting MRP1
CZ20003687A3 (cs) Způsoby inhibice MRP1
EP3221307A1 (en) Novel 1,3,5 -triazine based pi3k inhibitors as anticancer agents and a process for the preparation thereof
CA2758610A1 (en) Process 738
MXPA00009655A (en) Methods for inhibiting mrp1
PL231063B1 (pl) Pochodne 1-(podstawionej sulfonylo)-2-aminoimidazoliny jako środki przeciwnowotworowe
JP2004511486A (ja) デルタ−オピオイドアゴニストおよびアンタゴニストとしてのモルフィノイド誘導体
WO2020233716A1 (zh) 咪唑并哒嗪类mnk1/mnk2激酶抑制剂及其制备方法和应用
MXPA00009825A (en) Methods for inhibiting mrp1
CZ20003688A3 (cs) Způsob inhibice MRP1
CZ20003689A3 (cs) Způsob inhibice MRP1
AU3132700A (en) Slective beta3 adrenergic agonists